Top line stable.
+9.7% YoY versus +10.8% prior. 3y CAGR +9.0%.
+9.7%We use cookies
MainRatios uses cookies for essential site functions. With your consent, we also use analytics cookies including session replay sampling (PostHog, Google Analytics) and advertising cookies (Google AdSense). You can reject non-essential cookies, including the "sale" or sharing of personal information under CCPA, and you may withdraw consent at any time (GDPR). See our Privacy Policy for details.
Healthcare · Market Cap: $9.2B
Fundamentals as of 2025-12-31
All analysis on this page is for educational purposes only and does not constitute financial advice. Fair values are model-based estimates. Always do your own research.
3 of 4 legendary models say BUY UHS — but Charlie Munger disagrees.
What would legendary investors pay for UHS?
These figures are not quotes or opinions from Buffett, Graham, Lynch or the other investors. They are our own estimates, computed by applying the intrinsic-value formulas each investor is known for to this company’s financials.
For educational purposes only. Not a recommendation to buy or sell securities.
Bottom line: UHS is rated BUY by all 4 legendary models, 77% below avg fair value $633, but earns a B sector grade (64/100) in Healthcare. Whether the premium is justified depends on which lens you trust. Drill into the valuation breakdown and sector ranking for the full picture.
The Question
Yes — Universal Health Services, Inc.'s 20.5% ROE ranks above the S&P 500 median, and D/E 1.17 stays within healthy bounds.
Financial story
Yes — Universal Health Services, Inc.'s 20.5% ROE shows strong capital efficiency, and its 1.17 debt-to-equity stays within healthy bounds.
How does UHS compare?
UHS and MASI differ on P/E, ROE, and revenue growth. See the full UHS vs MASI compare matrix.
Buffett, Lynch, and Greenblatt evaluate UHS against their respective frameworks. Per-model fair value and reasoning are in the valuation tab.
UHS's P/E ratio is 7.6x. 5-year P/E history is in the financials tab.
3 of 4 legendary models say BUY. Full breakdown by investor and signal is in the valuation tab.
UHS's earnings calendar and history are tracked in the financials tab. Specific dates depend on company-published guidance.
UHS is in the Healthcare sector. Sector ranking and peer comparison are in the sector tab.
See exactly where UHS ranks
Sign in to unlock the full sector ranking — free.
Sign in to see the rankingUHS sits at #11 in Healthcare with a B grade (64/100).